Oncology is the largest pharma market and among most competitive. Despite huge progress, large unmet medical needs remain. Increasingly expensive treatments - check-point inhibitors, CAR-T, mRNA..., and complex decision making, require a high-end, value-based, omni-channel go-to-market model #blueJetconsulting #commercialexcellence #oncology #gotomarketstrategy Continue reading

With 50 % of global gastric, hepatic, and esophageal cancer cases and high lung cancer incidence, China Oncology market is a unique and challenging opportunity for multinational and local Biopharma. BlueJet Consulting can help portfolio, launch and go-to-market strategy. #commercialexcellence #oncology Continue reading

Checkpoint inhibitors against PD-1, PD-L1, CTLA-4 are dramatically improving cancer treatment in defined patient sub-sets. Combining them together and with chemo seems even more effective, as shown by coming Asco communications from Roche/Genentech and Bristol Myers Squibb Optimizing product portfolio and launch strategy is among BlueJet Consulting areas of expertise. Contact us for a free diagnosis. #postcovid19 #Oncology Continue reading